重大事件
即時報告
8-K
2026-06-15
Telomir Pharmaceuticals 提交8-K 自願披露非公開重要資訊
AI 繁中摘要
Telomir Pharmaceuticals（股票代號：TELO）於2026年6月15日向美國證監會提交8‑K表格，主要依據Regulation FD（公平披露規則）條文（Item 7.01）作出自願性披露，並同時上載附件EX‑99.1 📄。是次申報並未涉及Item 2.02業績或Item 8.01其他重大事件，因此內容應屬管理層向市場傳達的非公開重要資訊（例如臨床試驗進展、合作協議或監管更新）。由於8‑K屬即時報告，投資者應仔細查閱附件原文以掌握具體影響。該公司為佛羅里達州註冊的製藥企業，專注藥物製劑研發，本次披露或對短期股價產生波動，建議密切跟進後續公告。
展開英文正文
EDGAR Filing Documents for 0001493152-26-028614 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001493152-26-028614 Filing Date 2026-06-15 Accepted 2026-06-15 08:00:45 Documents 12 Period of Report 2026-06-15 Items Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K form8-k.htm iXBRL 8-K 38090 2 EX-99.1 ex99-1.htm EX-99.1 25720 Complete submission text file 0001493152-26-028614.txt 238907 Data Files Seq Description Document Type Size 3 XBRL SCHEMA FILE telo-20260615.xsd EX-101.SCH 3029 4 XBRL LABEL FILE telo-20260615_lab.xml EX-101.LAB 34239 5 XBRL PRESENTATION FILE telo-20260615_pre.xml EX-101.PRE 22368 15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3433 Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723 Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings) EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41952 | Film No.: 261089090 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)